Navigation Links
Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Date:5/10/2011

s.  Certolizumab pegol has not been formally studied in patients with CHF.  Exercise caution when using certolizumab pegol in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following certolizumab pegol administration.  If such reactions occur, discontinue further administration of certolizumab pegol and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including certolizumab pegol, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal.  Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating certolizumab pegol therapy.  Exercise caution in prescribing certolizumab pegol for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment.  In patients who develop HBV reactivation, discontinue certolizumab pegol and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic Reactions

Rare reports of pancytopenia, includi
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
2. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
3. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
6. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
7. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
8. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 /PRNewswire-iReach/ -- MicroTechnologies recently was awarded a significant ... devices at its Costa Rica facility. ... new Life Science division and will serve to greatly advance ... a major step forward, both for our company and ... remain confidential) has put their faith in the country and ...
(Date:6/17/2013)... June 17, 2013 Sanofi Pasteur, the vaccines ... SNY ), announced today the launch of Headfirst! ... help expand understanding of head lice infestation and how ... first time or managing a recurrent or persistent infestation ... Top experts in the fields of parenting, education and ...
(Date:6/17/2013)... DIEGO, Calif. , June 17, 2013 /PRNewswire/ ... today announced it has completed the acquisition of ... innovations from the compounding pharmacy operations of ... acquisition allows Imprimis to pursue the commercial development ... with a right of first refusal on additional ...
Breaking Medicine Technology:MicroTechnologies Announces Award of Medical Device Contract Manufacturing Line 2Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative 2Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative 3Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative 4Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative 5Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative 6Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 2Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 3Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 4Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 5
... YORK , Aug. 2 Reportlinker.com announces that a new market research report is ... Hepatitis C Therapeutics ... http://www.reportlinker.com/p0236386/Hepatitis-C-Therapeutics-Market---Taiwan.html , ... This research service aims to provide an update on ...
... SHANGHAI , Aug. 2 /PRNewswire-Asia/ -- WuXi ... a leading research and development outsourcing company serving the,pharmaceutical, ... the United States , today announced its financial ... . , (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO ...
Cached Medicine Technology:Hepatitis C Therapeutics Market - Taiwan 2Hepatitis C Therapeutics Market - Taiwan 3Hepatitis C Therapeutics Market - Taiwan 4Hepatitis C Therapeutics Market - Taiwan 5WuXi PharmaTech Announces Second-Quarter 2010 Results 2WuXi PharmaTech Announces Second-Quarter 2010 Results 3WuXi PharmaTech Announces Second-Quarter 2010 Results 4WuXi PharmaTech Announces Second-Quarter 2010 Results 5WuXi PharmaTech Announces Second-Quarter 2010 Results 6WuXi PharmaTech Announces Second-Quarter 2010 Results 7WuXi PharmaTech Announces Second-Quarter 2010 Results 8WuXi PharmaTech Announces Second-Quarter 2010 Results 9WuXi PharmaTech Announces Second-Quarter 2010 Results 10WuXi PharmaTech Announces Second-Quarter 2010 Results 11WuXi PharmaTech Announces Second-Quarter 2010 Results 12WuXi PharmaTech Announces Second-Quarter 2010 Results 13WuXi PharmaTech Announces Second-Quarter 2010 Results 14WuXi PharmaTech Announces Second-Quarter 2010 Results 15WuXi PharmaTech Announces Second-Quarter 2010 Results 16
(Date:6/17/2013)... June 17, 2013 Nearly 26 million ... many as 79 million adults are estimated to have ... prevent type 2 diabetes through weight loss and lifestyle ... help bring your blood sugar level back within the ... factors, 101 Medical Weight Loss physicians can help tailor ...
(Date:6/17/2013)... NY (PRWEB) June 17, 2013 ... & Murphy, LLP are pleased to announce that ... and David L. Scher ( http://www.blockotoole.com/Attorneys/David-L-Scher.shtml ) will ... Z100 (100.3 FM) this Sunday, June 23, 2013 ... will be guests on Kevin Burke's "Get Active" ...
(Date:6/17/2013)... 17, 2013 The producers of Impact ... series of reports highlighting how sustainable farming techniques are ... populations and their demand on food supplies. , ... television series airing in markets around the country on ... Martin Sheen, who is marking the start of his ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Dallas-based physician ... the nation to offer the hybrid concierge model from ... model to offer her patients a wider variety of ... and a greater emphasis on prevention and wellness had ... who want a concierge-style of medicine, but doesn't force ...
(Date:6/17/2013)... Stem Cell Institute (HSCI) researchers have identified in the ... regulate embryonic stem cell self-renewal, beginning a creative search ... The gene, SALL4, gives stem cells their ability to ... cells. Typically, cells only express SALL4 during embryonic development, ... of acute myeloid leukemia and 10 to 30 percent ...
Breaking Medicine News(10 mins):Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 3Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 4Health News:Injury Attorneys Block O'Toole & Murphy, LLP to Appear on Z100 Radio Show This Sunday to Discuss Their Support of St. Jude Children's Research Hospital 2Health News:Dr. Casad Offers Hybrid Concierge Model from Concierge Choice Physicians 2Health News:Dr. Casad Offers Hybrid Concierge Model from Concierge Choice Physicians 3Health News:A new target for cancer drug development 2
... its determination to gear up to meet the avian flu ... keep a close watch on bird flu cases and also ... M A Hakeem said "Though we have no cases of ... measures and the committee to be formed will include representatives ...
... a high childhood IQ irrespective of income and social position. ... and Laura Kubzansky, Harvard's School of Public Health who reported ... ,Childhood IQ of more than 163 score is very ... with a score more than 130 are considered gifted and ...
... cancers are mainly caused by cigarette smoking and smoking ... occurrence. In order to reduce the risk of cigarette ... of testing //their new range of “safer cigarette” which ... ,The company is testing their new ...
... practical and cost effective new way to combat the HIV ... modified bacteria living in the human body to produce chemicals ... occurs on the surfaces of the gut and reproductive areas, ... ,The researchers have successfully modified one of these bacteria ...
... age-related macular degeneration and the genetic mechanisms underlying the ... identification of a bacterium //called Chlamydia pneumoniae in the ... notable that the microorganism is associated with chronic inflammation ... in the diseased eye tissue of five of nine ...
... of bird flu in the famous Ranganathittu bird sanctuary ... Department today said that it was totally geared up ... ,The Department has taken precautionary measures against bird flu ... several countries including Central and Northern China, Russia, Mongolia, ...
Cached Medicine News:Health News:Avian Influenza: Government to set up expert committee 2Health News:Genetically modified bacteria to combat HIV 2Health News:Bird flu threat ruled out: Karnataka Forest Department, 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: